Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Mass spectrometry for the detection of minimal residual disease (MRD) in myeloma
Dr Noemí Puig - Hospital Universitario de Salamanca, Salamanca, Spain
Mass spectrometry for the detection of minimal residual disease (MRD) in myeloma ( Dr Noemí Puig - Hospital Universitario de Salamanca, Salamanca, Spain )
25 Sep 2020
Managing multiple myeloma in a COVID-19 world
Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France
Managing multiple myeloma in a COVID-19 world ( Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France )
25 Sep 2020
ESMO 2020 renal roundup
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
ESMO 2020 renal roundup ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
25 Sep 2020
Exon 20 insertions in NSCLC - ESMO 2020
Dr Alex Spira, Prof Benjamin Besse, Prof Michael Thomas and Dr Antonio Passaro
Exon 20 insertions in NSCLC - ESMO 2020 ( Dr Alex Spira, Prof Benjamin Besse, Prof Michael Thomas and Dr Antonio Passaro )
25 Sep 2020
ESMO 2020: Lung cancer latest
Prof Solange Peters, Dr Federico Cappuzzo, Dr Antonio Passaro and Prof Sanjay Po...
ESMO 2020: Lung cancer latest ( Prof Solange Peters, Dr Federico Cappuzzo, Dr Antonio Passaro and Prof Sanjay Popat )
25 Sep 2020
Highlights from ESMO 2020
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Highlights from ESMO 2020 ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
25 Sep 2020
Latest in bladder cancer with FGFR 2 and 3 mutations
Dr Yohann Loriot and Dr Scott Tagawa
Latest in bladder cancer with FGFR 2 and 3 mutations ( Dr Yohann Loriot and Dr Scott Tagawa )
24 Sep 2020
PARP inhibitors and their evolving role for the treatment of prostate cancer
Dr Neal Shore, Dr Neeraj Agarwal, Dr Elena Castro and Dr Kim Chi
PARP inhibitors and their evolving role for the treatment of prostate cancer ( Dr Neal Shore, Dr Neeraj Agarwal, Dr Elena Castro and Dr Kim Chi )
24 Sep 2020
KEYNOTE-590: Pembrolizumab plus chemotherapy for advanced oesophageal cancer
Prof Ken Kato - National Cancer Center Hospital, Chuo-ku, Japan
KEYNOTE-590: Pembrolizumab plus chemotherapy for advanced oesophageal cancer ( Prof Ken Kato - National Cancer Center Hospital, Chuo-ku, Japan )
24 Sep 2020
Disparities in access to oncology clinical trials across Europe
Prof Ana Carneiro - Lund University, Lund, Sweden
Disparities in access to oncology clinical trials across Europe ( Prof Ana Carneiro - Lund University, Lund, Sweden )
24 Sep 2020
ESMO 2020: Latest updates in prostate cancer
Dr Eleni Efstathiou, Prof Boris Hadaschik, Prof Johann De Bono and Prof Nick Jam...
ESMO 2020: Latest updates in prostate cancer ( Dr Eleni Efstathiou, Prof Boris Hadaschik, Prof Johann De Bono and Prof Nick James )
23 Sep 2020
ASCENT: Sacituzumab govitecan vs treatment of physician’s choice in patients wit...
Dr Aditya Bardia - Massachusetts General Hospital, Boston, USA
ASCENT: Sacituzumab govitecan vs treatment of physician’s choice in patients with previously treated mTNBC ( Dr Aditya Bardia - Massachusetts General Hospital, Boston, USA )
23 Sep 2020